Sanofi - ADR


Market Cap$123.17B

Compare Sanofi

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Sanofi - ADRSanofi - ADR20.67.93%---
marketMarket Avg54.31.27%32%-1.3
HealthcareHealthcare Avg39.11.36%17%7.21.3

Earnings Call Q4 2023

February 1, 2024 - AI Summary

Sanofi reported strong Q4 and full-year 2023 results, driven by the performance of Dupixent and key launches such as Beyfortus.
Dupixent sales reached almost EUR3 billion in Q4 alone, with full-year sales up 34%. The company expects Dupixent to reach around EUR13 billion in sales in 2024.
Beyfortus had a successful launch, with record uptake and sales of over EUR400 million in Q4. Supply is being expanded to meet demand, and the vaccine is expected to reach blockbuster status in 2024.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

12.7% upsideSanofi Target Price DetailsTarget Price

Current Fair Value

187.1% upside

Undervalued by 187.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$123.17 Billion
Enterprise Value-
Dividend Yield$3.8602 (7.93%)
Earnings per Share$2.38
Outstanding Shares2,529,606,602
Avg 30 Day Volume2,492,548


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio20.63
Price to Sales-
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income-
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

ESG Score

No data

About Sanofi

CEO: Paul Hudson

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the c...